PRIMAXIN 500 POWDER FOR SOLUTION

Země: Kanada

Jazyk: angličtina

Zdroj: Health Canada

Aktivní složka:

IMIPENEM; CILASTATIN (CILASTATIN SODIUM)

Dostupné s:

MERCK CANADA INC

ATC kód:

J01DH51

INN (Mezinárodní Name):

IMIPENEM AND CILASTATIN

Dávkování:

500MG; 500MG

Léková forma:

POWDER FOR SOLUTION

Složení:

IMIPENEM 500MG; CILASTATIN (CILASTATIN SODIUM) 500MG

Podání:

INTRAVENOUS

Jednotky v balení:

25 VIALS (100 OR 250 ML)

Druh předpisu:

Prescription

Terapeutické oblasti:

CARBAPENEMS

Přehled produktů:

Active ingredient group (AIG) number: 0218820001; AHFS:

Stav Autorizace:

MARKETED

Datum autorizace:

2006-12-13

Charakteristika produktu

_ _
_PRIMAXIN_
_®_
_ (imipenem and cilastatin sodium for injection, USP) _
_Page 1 of 61 _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PRIMAXIN®
imipenem and cilastatin for injection, USP
500 mg imipenem and 500 mg cilastatin (as cilastatin sodium) per vial
Sterile powder for solution, I.V. Infusion
ANTIBIOTIC
Merck Canada Inc.
16750 route Transcanadienne
Kirkland QC Canada H9H 4M7
www.merck.ca
Date of Initial Authorization:
JUL 07,1987
Date of Revision:
DEC 21, 2021
Submission Control Number: 253551
_ _
_PRIMAXIN_
_®_
_ (imipenem and cilastatin sodium for injection, USP) _
_Page 2 of 61 _
RECENT MAJOR LABEL CHANGES
4. DOSAGE AND ADMINISTRATION, 4.1 Dosing Considerations
12/2021
4. DOSAGE AND ADMINISTRATION
06/2020
7. WARNINGS AND PRECAUTIONS
06/2020
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED
.
[To update, right-click anywhere in the Table of Contents and select
“Update Field”, “Update entire
table”, click OK.]
RECENT MAJOR LABEL CHANGES
...........................................................................................
2
TABLE OF CONTENTS
.............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.....................................................................
5
1
INDICATIONS
..............................................................................................................
5
1.1 Pediatrics
.......................................................................................................................
6
1.2 Geriatrics
.......................................................................................................................
6
2
CONTRAINDICATIONS
.................................................................................................
6
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
............................................................ 7
4
DOSAGE AND ADMINISTRATION
................